TY - JOUR
T1 - Prospective, Multicenter Clinical Study of Microvascular Decompression for Hemifacial Spasm
AU - Mizobuchi, Yoshifumi
AU - Nagahiro, Shinji
AU - Kondo, Akinori
AU - Arita, Kazunori
AU - Date, Isao
AU - Fujii, Yukihiko
AU - Fujimaki, Takamitsu
AU - Hanaya, Ryosuke
AU - Hasegawa, Mitsuhiro
AU - Hatayama, Toru
AU - Hongo, Kazuhiro
AU - Inoue, Tooru
AU - Kasuya, Hidetoshi
AU - Kobayashi, Masahito
AU - Kohmura, Eiji
AU - Matsushima, Toshio
AU - Masuoka, Jun
AU - Morita, Akio
AU - Munemoto, Shigeru
AU - Nishizawa, Shigeru
AU - Okayama, Yoshihiro
AU - Sato, Kimitoshi
AU - Shigeno, Taku
AU - Shimano, Hiroshi
AU - Takeshima, Hideo
AU - Tanabe, Hideki
AU - Yamakami, Iwao
N1 - Publisher Copyright:
© 2021 Congress of Neurological Surgeons 2021.
PY - 2021/4/1
Y1 - 2021/4/1
N2 - BACKGROUND: Microvascular decompression (MVD) is the most effective procedure for hemifacial spasm (HFS). MVD results from nonspecialized or low-volume institutes are not always reliable. Most studies on MVD for HFS are retrospective and single centered; to the best of our knowledge, no prospective, multicenter studies exist. OBJECTIVE: To evaluate short- A nd long-term outcomes and complications in patients who underwent MVD for HFS in specialized Japanese institutions, in this multicenter, prospective, cohort study. METHODS: Included patients had undergone MVD for HFS in study centers between April 2012 and March 2015. Patients' postoperative grade of involuntary movements and complications were recorded postoperatively at 7 d (short-term) and at 1 (mid-term) and 3 (long-term) yr. RESULTS: A total of 486 patients (150 men, 336 women; mean age 53.9 yr with 181 patients over 60 yr) were enrolled during the study period. Neuromonitoring was used in 96.3% of the cases. The complete cure rate of symptom relief, mortality rate, and complication rate at short-term follow-up were 70.6%, 0%, and 15%, respectively. The long-term follow-up was completed by 463 patients (95.3%); the complete cure rate of symptom relief and complication rate were 87.1% and 3.0%, respectively. CONCLUSION: Our study revealed that under expert guidance and intraoperative neuromonitoring, the long-term curative effect rate of MVD for HFS is high, while complications are uncommon and usually transient. Our results indicate that MVD is an effective and safe treatment for patients with HFS, including elderly patients.
AB - BACKGROUND: Microvascular decompression (MVD) is the most effective procedure for hemifacial spasm (HFS). MVD results from nonspecialized or low-volume institutes are not always reliable. Most studies on MVD for HFS are retrospective and single centered; to the best of our knowledge, no prospective, multicenter studies exist. OBJECTIVE: To evaluate short- A nd long-term outcomes and complications in patients who underwent MVD for HFS in specialized Japanese institutions, in this multicenter, prospective, cohort study. METHODS: Included patients had undergone MVD for HFS in study centers between April 2012 and March 2015. Patients' postoperative grade of involuntary movements and complications were recorded postoperatively at 7 d (short-term) and at 1 (mid-term) and 3 (long-term) yr. RESULTS: A total of 486 patients (150 men, 336 women; mean age 53.9 yr with 181 patients over 60 yr) were enrolled during the study period. Neuromonitoring was used in 96.3% of the cases. The complete cure rate of symptom relief, mortality rate, and complication rate at short-term follow-up were 70.6%, 0%, and 15%, respectively. The long-term follow-up was completed by 463 patients (95.3%); the complete cure rate of symptom relief and complication rate were 87.1% and 3.0%, respectively. CONCLUSION: Our study revealed that under expert guidance and intraoperative neuromonitoring, the long-term curative effect rate of MVD for HFS is high, while complications are uncommon and usually transient. Our results indicate that MVD is an effective and safe treatment for patients with HFS, including elderly patients.
KW - Elderly patients
KW - Hemifacial spasm
KW - Microvascular decompression
UR - http://www.scopus.com/inward/record.url?scp=85102964602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102964602&partnerID=8YFLogxK
U2 - 10.1093/neuros/nyaa549
DO - 10.1093/neuros/nyaa549
M3 - Article
C2 - 33469667
AN - SCOPUS:85102964602
SN - 0148-396X
VL - 88
SP - 846
EP - 854
JO - Neurosurgery
JF - Neurosurgery
IS - 4
ER -